Login to Your Account

Pharming Stock Moves Up On Positive Rhucin Data

By Cormac Sheridan

Wednesday, August 22, 2007
Shares in Pharming Group NV rose more than 27 percent Monday on news that it stopped a placebo-controlled clinical trial of Rhucin in hereditary angioedema (HAE) on ethical grounds, following advice from an independent data monitoring committee. An interim analysis of the data indicated that none of the patients treated during the study experienced a relapse, and no adverse events were reported. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription